Professor Silvia Marino
Professor of Neuropathology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
Hon Consultant Neuropathologist, Barts Health NHS Trust
Hon Consultant Neuropathologist, The National Hospital for Neurology and Neurosurgery
2015 FRCPath, UK
2004 Swiss Medical Association Board Certification in Histopathology, Switzerland
2002 EFPath (European Board of Pathology)
1992 MD (cum laude), University of Turin, Turin, Italy
After studying Medicine at the University of Turin in Italy, Professor Marino trained in Neuropathology and Histopathology at the University of Zurich in Switzerland. She trained in molecular genetics at The Netherlands Cancer Institute in Amsterdam as a Marie Curie Postdoctoral Fellow of the European Community. She established her own laboratory research group in 2002 firstly at the Institute of Pathology, University of Zurich and then since 2006 at the Blizard Institute in London.
Research and Clinical Interests
Silvia Marino is Professor of Neuropathology, Lead of the NIHR Integrated Academic Clinical Training and member of the Research Deanery at Barts and The London School of Medicine and Dentistry, Queen Mary University of London.
She is the Lead of the Brain Tumour Research Centre of Excellence, a partnership between QMUL together with UCL Institute of Neurology and the charity Brain Tumour Research.
The focus of the Marino research group is on the biology of stem cells and progenitor cells, on the pathways and genes involved in control of their maintenance, proliferation and differentiation, in particular the Polycomb group genes. The group is currently investigating the role of deregulated epigenetic mechanisms in initiation and progression of brain tumours –medulloblastoma and glioblastoma- in experimental models and in human tumour samples.
In her clinical role as a consultant neuropathologist, she specialises in the neuropathological assessment of neuro-oncological surgical specimen and muscle biopsies.
Chair of the academic committee of the British Neuropathology Society (BNS)
Member of the Swedish Research Council Grant Review Panel (Health)
Member of the NCRI Clinical Studies Group in Brain Tumours
Member of the academic committee of the European Association of Neuro-Oncology (EANO)
Member of the Editorial Board Neuropathology and Applied Neurobiology
MV Niklison-Chirou, I Erngren, M Engskog, J Haglöf, D Picard, M Remke, P H R McPolin, M Selby, D Williamson, S C Clifford, D Michod, M Hadjiandreou, T Arvidsson, C Pettersson, G Melino and S Marino.
TAp73 is a marker of glutamine addiction in medulloblastoma
Genes & Development, 2017 Sep 26. doi: 10.1101/gad.302349.117. [Epub ahead of print].
An Outlook article in Genes & Development will accompany the printed version of this paper.
S Dibenedetto, M Niklison-Chirou, CP Cabrera, M Ellis, LG Robson, P Knopp, FS Tedesco, M Ragazzi, V Di Foggia, MR Barnes, A Radunovic, S Marino.
Enhanced Energetic State and Protection from Oxidative Stress in Human Myoblasts Overexpressing BMI1.
Stem Cell Reports. 2017 Aug 8;9(2):528-542. doi: 10.1016/j.stemcr.2017.06.009. Epub 2017 Jul 20.
D Guillotin, P Austin, R Begum, MO Freitas, A Merve, T Brend, SC Short, S Marino, SA Martin.
Drug-repositioning screens identify Triamterene as a selective drug for the treatment of DNA Mismatch Repair deficient cells.
Clin Cancer Res. 2016 Dec 2. pii: clincanres.1216.2016. [Epub ahead of print]
V Di Foggia, X Zhang, D Licastro, M F M Gerli, R Phadke, F Muntoni, P Mourikis, S Tajbakhsh, M Ellis, L C Greaves, R W Taylor, G Cossu, L G Robson and S Marino.
Bmi1 enhances skeletal muscle regeneration through MT1 mediated oxidative stress protection in a mouse model of dystrophinopathy.
J Exp Med. 2014 Dec 15;211(13):2617-33
S Acquati, A Greco, D Licastro, H Bhagat, D Ceric, Z Rossini, J Grieve, M Shaked-Rabi, N V Henriquez, S Brandner, E Stupka and S Marino.
Epigenetic regulation of Survivin by Bmi1 is cell type specific during corticogenesis and in gliomas.
Stem Cells 2013 Jan 31(1):190-202